Moleculin Biotech secures Hong Kong patent for liposomal Annamycin through 2040

Moleculin Biotech, Inc.

Hong Kong patent No. 40073244 covers proprietary reconstitution method of liposomal Annamycin, expiring June 25, 2040.
Invention jointly owned with The University of Texas System; extends IP protection across four continents.
Company expects first Phase 3 clinical data release for Annamycin later this quarter.
Existing granted/allowed patents include US, Australia, Canada, China, Europe, India, Israel, Japan, Mexico, Singapore, Taiwan.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.